The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study
Background: The incidence of TB among Inuit is the highest in Canada. A significantly shorter latent TB infection (LTBI) treatment with rifapentine and isoniazid once weekly for 12 weeks (3HP) is now available in limited settings in Canada. Methods: A prospective open-label 2-year observational post...
Published in: | International Journal of Circumpolar Health |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Text |
Language: | English |
Published: |
Taylor & Francis
2020
|
Subjects: | |
Online Access: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241515/ http://www.ncbi.nlm.nih.gov/pubmed/32379538 https://doi.org/10.1080/22423982.2020.1758501 |